IDT Secures New Contract with Sanofi Australia

Posted: 14 August 2024

IDT Australia Limited (ASX: IDT) (IDT or the Company) is pleased to announce that it has secured a follow-on contract with Sanofi Australia (Sanofi) worth between $2.5 million and $4 million for the preclinical formulation, development and manufacture of Sanofi’s messenger RNA (mRNA) technology for its translational clinical program.

The contract comes on the back of IDT being awarded a Master Service Agreement (MSA) with Sanofi, which was announced on 16 April 2024. The MSA provides flexibility for Sanofi to choose services from IDT and allows for follow-on work packages.

Find out more.

Category: News, Member News

Home

News & opinion

Member Directory

Events

CLICK HERE TO SUBSCRIBE TO OUR NEWSLETTER

BioMelbourne Network respectfully acknowledges the Traditional Custodians of the unceded lands and waters of Victoria: the Bunurong, Gunaikurnai and Wurundjeri peoples, on which the BioMelbourne Network and our Victorian members work, and as well as the lands and waters of our members further afield. We pay respect to their Elders past and present. As Australia’s first scientists, we acknowledge the significant contribution that they and other Aboriginal and Torres Strait Islander people have made and continue to make to the research and knowledge systems that inform our community and our sector.

We acknowledge that Aboriginal and Torres Strait Islander people continue to live in a spiritual and sacred relationship with this country and recognise our responsibility to continue to work towards reconciliation.